At the Trevena Inc (NASDAQ:TRVN) 2014 Annual Meeting of Stockholders held on May 24, 2014 (the “Annual Meeting”), stockholders approved the Company’s 2013 Equity Incentive Plan, as amended (the “Plan”), which had been previously approved by our Board of Directors subject to stockholder approval. Trevena Inc (NASDAQ:TRVN) weekly performance is -5.51% .On last trading day company shares ended up $4.46. Analysts mean target price for the company is $15.00. Trevena Inc (NASDAQ:TRVN) distance from 50-day simple moving average (SMA50) is -31.56%.
DARA Biosciences Inc (NASDAQ:DARA) announced its support for Neuropathy Awareness Week which is being observed during the week of May 12, 2014 and sponsored in the U.S. by The Neuropathy Association.DARA Biosciences Inc (NASDAQ:DARA) shares fell -7.08% in last trading session and ended the day on $1.05. DARA Gross Margin is 50.00% and its return on assets is -107.20%. DARA Biosciences Inc (NASDAQ:DARA) quarterly performance is -59.92%.
Enzymotec Ltd (NASDAQ:ENZY) reports that it was informed that AarhusKarlshamn AB, or AAK, a Sweden-based, global producer of specialty oils that is Enzymotec’s joint venture partner in Advanced Lipids AB, submitted a claim for arbitration against the Company seeking certain declaratory relief with respect to the joint venture agreement. Enzymotec Ltd (NASDAQ:ENZY) shares moved down -6.18% in last trading session and was closed at $12.90, while trading in range of $12.10 – $13.99. Enzymotec Ltd (NASDAQ:ENZY) year to date (YTD) performance is -52.24%.
Clovis Oncology Inc (NASDAQ:CLVS) was a big mover last session as the company saw its shares surge on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This broke the recent trend of the company. Clovis Oncology Inc (NASDAQ:CLVS) ended the last trading day at $55.96. Company weekly volatility is calculated as 7.61% and price to cash ratio as 5.87.Clovis Oncology Inc (NASDAQ:CLVS) showed a positive weekly performance of 17.00%
On 12 MAY 2014 Ignyta Inc (NASDAQ:RXDX), an oncology precision medicine biotechnology company, announced company highlights and financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, net loss was $4.1 million, or $0.28 per share, compared with $1.0 million, or $1.55 per share, for the first quarter of 2013.Ignyta Inc (NASDAQ:RXDX) weekly performance is -2.87%. On last trading day company shares ended up $7.11. Analysts mean target price for the company is $17.00. Ignyta Inc (NASDAQ:RXDX) distance from 50-day simple moving average (SMA50) is -10.81%.